Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,562Revenue (TTM) $M--Net Margin (%)--Altman Z-Score
Enterprise Value $M-12.6EPS (TTM) $--Operating Margin %--Piotroski F-Score--
P/E(ttm)22.7Beneish M-Score--Pre-tax Margin (%)--Higher ROA y-yN
Price/Book3.510-y EBITDA Growth Rate %--Quick Ratio--Cash flow > EarningsN
Price/Sales--5-y EBITDA Growth Rate %--Current Ratio--Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)--Higher Current Ratio y-yN
Dividend Yield %1.9PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M15,500,000ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with IXJ

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
IXJKen Fisher 2016-06-30 Add$96.03 - $102.9
($99.72)
$ 100.741%Add 45.39%17,624
IXJKen Fisher 2016-03-31 Reduce-0.02%$90.5 - $102.62
($95.44)
$ 100.746%Reduce -86.86%12,122
IXJKen Fisher 2015-12-31 Add0.02%$99.78 - $105.97
($102.96)
$ 100.74-2%Add 380.03%92,228
IXJKen Fisher 2015-09-30 Add$96.45 - $113.73
($107.78)
$ 100.74-7%Add 187.71%19,213
IXJKen Fisher 2015-06-30 Add$107.16 - $112.88
($109.98)
$ 100.74-8%Add 9.14%6,678
IXJKen Fisher 2015-03-31 Reduce$98.86 - $110.66
($104.83)
$ 100.74-4%Reduce -13.27%6,119
IXJKen Fisher 2014-03-31 Buy $84.91 - $93
($89.14)
$ 100.7413%New holding5,950
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

IXJ is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


IXJ: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Keogh, WillemSenior Officer 2016-09-08Buy338$21.28373.4view
Sardo, Vincent JamesDirector 2016-09-08Sell1,500$43.05134.01view
Larson, Douglas RobertDirector, Senior Officer 2016-09-08Sell800$8.351106.47view
Fraser, AlisonDirector or Senior Officer of Insider or Subsidiar 2016-09-08Sell12,700$10.18889.59view
Brown, ArthurDirector 2016-09-08Sell250,000$0.07143814.29view
Brewster, NormanSenior Officer 2016-09-08Sell45,000$0.03335700view
Darling, Neil B.T.Director 2016-09-08Buy53,500$0.2737211.11view
Porter, Brian JDirector, Senior Officer 2016-09-08Sell25,176$70.1743.57view
Marsh, John M.Director 2016-09-08Sell36,000$29.5241.49view
Graham, Eric JohnSenior Officer 2016-09-08Buy1,700$3.233018.89view

Quarterly/Annual Reports about IXJ:

    News about IXJ:

    Articles On GuruFocus.com
    Abbott Receives FDA Approval for Freestyle Libre Sep 30 2016 
    Himax’s Pullback Is an Opportunity Sep 30 2016 
    Halliburton Is in Good Shape Sep 30 2016 
    Betting on Chevron Makes Sense Sep 30 2016 
    Lifeway Looks Good Sep 30 2016 
    Warning Signs Identify Value Declining Companies Sep 30 2016 
    EnSync Insider Purchases 1,306,737 Shares Sep 30 2016 
    Pearson PLC's Stock Yields Over 7% Sep 30 2016 
    Dunkin’ Donuts to Release Bottled Beverages Sep 30 2016 
    Insider Slashes 65,000 Computer Science Shares Sep 30 2016 

    More From Other Websites
    AstraZeneca Is Taking Steps to Improve Its Position in Oncology Sep 19 2016
    Roche Sees Soaring Revenue from Its Bladder Cancer Treatment Sep 16 2016
    What Investors Can Glean from GlaxoSmithKline’s Revenue Trend Sep 09 2016
    Is Johnson & Johnson’s Valuation High Compared to Its Peers? Aug 30 2016
    [$$] Why Investors Should Think Global Aug 26 2016
    AstraZeneca’s Recent Product Developments Aug 25 2016
    AstraZeneca and Its Oncology Segment’s Growth in 2Q16 Aug 25 2016
    How Crestor Weakened AstraZeneca’s CVMD Segment in 2Q16 Aug 24 2016
    Remicade Is Driving Down Merck’s Immunology Franchise Aug 16 2016
    How Are Eli Lilly’s New Products Performing? Aug 04 2016
    Revenues from Eli Lilly’s Cymbalta Are Depressed Internationally Aug 03 2016
    What to Expect from Pfizer’s 2Q16 Earnings Aug 01 2016
    How Did JNJ’s Pharmaceutical Segment Fare in 2Q16? Jul 22 2016
    Understanding Lilly’s New Product Expectations for 2Q16 Jul 22 2016
    Inside Lilly’s 2Q16 Estimates for Its Neuroscience Franchise Jul 22 2016
    Why AbbVie Continues to Explore Imbruvica for Diffuse Large B-Cell Lymphoma Jul 06 2016
    AstraZeneca’s Key Focus: Oncology Jun 06 2016
    What’s AstraZeneca’s Largest Revenue Contributor? Jun 01 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)